Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic LeukemiaJan A. Burger, Thomas J. Kipps, Sebastian Grosicki et al.|New England Journal of Medicine|2015Cited by 1.6k
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myelomaHang Quach, H. Miles Prince, David Ritchie et al.|Leukemia|2009Cited by 586
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working GroupPhilippe Moreau, Jean‐Luc Harousseau, Shaji Kumar et al.|The Lancet Oncology|2021Cited by 266
T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironmentsEdwin D. Hawkins, Cristina Lo Celso, Delfim Duarte et al.|Nature|2016Cited by 205
The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapyAndy Hsu, Hang Quach, Tsin Yee Tai et al.|Blood|2010Cited by 156